Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology.

Transl Oncol · 2025 · PMC12478137 · PMID 40966800

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

showed a trendp = 0.062so close (0.05 < p ≤ 0.1)

Radiosensitive PDOs showed a trend toward lower baseline expression compared to resistant lines (8.4 % vs. 57.2 %, p = 0.062; Fig. 2 C1), but no additional differences among subgroups were detected at baseline or after RT.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.